Novak Djokovic has controlling stake in firm developing Covid drug

Novak Djokovic is the controlling shareholder in a Danish biotech firm aiming to develop a treatment for Covid-19 that does not involve vaccination, the Financial Times reported.

The world No 1, who was deported from Australia this week after the government cancelled his visa in a dispute over a medical exemption relating to his unvaccinated status, bought an 80 per cent stake in QuantBioRes in 2020.

Ivan Loncarevic, the company’s chief executive, confirmed the investment to Reuters. He subsequently told the Financial Times that he had not spoken to Djokovic, who has won more than $150m in prize money, since November and that the tennis star was “not anti-vax”.

Read also

"I would say almost a miracle" - Alex Corretja describes Andy Murray's sudden resurgence

QuantBioRes has about 11 researchers working in Denmark, Australia and Slovenia, according to Loncarevic, who stressed the company was working on a treatment, not a vaccine. The company’s website says it started developing a “deactivation mechanism” for Covid-19 in July 2020.

The company is developing a peptide, which inhibits the coronavirus from infecting the human cell, and it expects to launch clinical trials in Britain this summer, Loncarevic said. A spokesperson for Djokovic did not immediately respond to a request for comment.